JP2017515911A - クルクミン−ペプチドコンジュゲートおよびその製剤 - Google Patents
クルクミン−ペプチドコンジュゲートおよびその製剤 Download PDFInfo
- Publication number
- JP2017515911A JP2017515911A JP2017512657A JP2017512657A JP2017515911A JP 2017515911 A JP2017515911 A JP 2017515911A JP 2017512657 A JP2017512657 A JP 2017512657A JP 2017512657 A JP2017512657 A JP 2017512657A JP 2017515911 A JP2017515911 A JP 2017515911A
- Authority
- JP
- Japan
- Prior art keywords
- curcumin
- curcuminoid
- protein
- peptide
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4717—Plasma globulins, lactoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
Abstract
Description
本願は、2014年5月12日にPayneらによって出願された「CURCUMIN−PEPTIDE CONJUGATES AND FORMULATIONS THEREOF」と題する米国仮特許出願第61/992,123号の優先権を主張するものであり、上記出願の開示全体が参照により本明細書に組み込まれる。
本発明は、機能性食品の製剤の分野、より具体的には生体利用可能なクルクミノイドを有する製剤の分野に属する。
本発明者らは、クルクミン−ペプチド複合体の服用が非複合体クルクミンの服用に比して血清中バイオアベイラビリティを有意に増大させることを発見した。
ヒト対象に投与するためのクルクミン−WPI複合体を調製した。以下の原料を用いた:
WPI:85重量%タンパク質
クルクミン粉末:95%クルクミノイド
エタノール:100%エチルアルコール
実施例1の方法に従って、クルクミンを95%エタノール中に溶かした後、N−アセチルシステイン(NAC)を加えた。n−アセチルシステインに対するクルクミンの濃度の比の漸増を用いて、飽和レベルを明らかにした。エタノール中のクルクミンの0.5%(w/v)溶液での至適濃度は、NAC 1000mgに対しクルクミン 100mg前後であることがわかった。顕微鏡視野で観察されるクルクミン結晶の形成数が少ないときに至適濃度が確認された。
健常被験者2例に、クルクミン:WPIの比が25:1(w/w)(mg:g)のクルクミン:WPI複合体を1用量投与した。用量はクルクミン25mgを含んだ。20分後、50分後、および90分後に各被験者から血液を採取し、血清クルクミンレベルを算出した。その結果を下の表1に示す。
57歳男性、膝および股関節に関節炎/滑液包炎があり、炎症性腸疾患が認められた。投与前に中等度の膝および股関節の疼痛ならびに中等度の下痢を伴う腹部痙攣が認められた。異なる用量および製剤を数種類投与した。用量および観察された効果を表2にまとめる。
症例1:70歳白人女性、季節性うつ病の病歴があり、Prozac(登録商標)によって十分にコントロールされていた。実施例1の複合体1.2gを1日2回投与し、使用3日後に症状の完全寛解をみた。同患者は症状緩和を維持するため同製品を服用し続け、Prozac(登録商標)の使用を中止できた。
症例1:11歳QH去勢ウマ、左右の前足首に骨関節炎が認められた。足首屈曲時の疼痛および駆け足時の「歩調の乱れ」がみられた。実施例1の製品200mgを1日2回、経口投与した。1週間後に、落着きまたは不安の軽減とともに、足首屈曲時の疼痛の軽減および駆け足時の円滑な歩調が認められた。有害な副作用は認められなかった。
クルクミン:WPI複合体:マウス6匹にそれぞれクルクミン:WPI複合体12.5mg(マウス1匹当たりクルクミン約312μg)を投与した。各マウスの体重は約25gであった。30分毎に計180分間、血液を採取した。クルクミンの平均値(ng/mL)を表3に示す。平均Tmaxは60分であり、平均Cmaxはクルクミン163ng/mLであった。
健常被験者2例に用量の異なる様々なクルクミン製剤を投与した。様々な時点で指先採血法により各被験者から血液を採取した。クルクミンの血漿中濃度を算出し、Cmaxを求めた。その結果を表5に示す。
Claims (20)
- クルクミノイド−ペプチド複合体を含む組成物。
- 前記クルクミノイドが、クルクミン、デスメトキシクルクミン(DMC)、ビスデスメトキシクルクミン(BDMC)、テトラヒドロクルクミン(THC)、テトラヒドロデスメトキシクルクミン(TDMC)、テトラヒドロビスデスメトキシクルクミンおよび(TBDMC)からなる群より選択される、請求項1に記載の組成物。
- 前記ペプチドが、ジペプチド、トリペプチド、オリゴペプチド、ポリペプチド、タンパク質、およびタンパク質フラグメントからなる群より選択される、請求項1に記載の組成物。
- 前記ペプチドが、乳清タンパク質、腫瘍壊死因子(TNF−α);シクロオキシゲナーゼ(COX)(COX−1およびCOX−2を含む);α1酸性糖タンパク質(AGP)(オロソムコイドとしても知られる);ミエロイド分化タンパク質2(MD−2);ヒストンアセチル−トランスフェラーゼ(HAT)と呼ばれる酵素のグループのうちのいずれか1つ、p300/CBPなど;ヒストンデアセチラーゼ(HDAC)と呼ばれる酵素のグループのうちのいずれか1つ;グリオキサラーゼI(GLOI);キサンチンオキシダーゼ(XO);プロテアソーム;筋小胞体(小胞体)Ca2+ATPアーゼ(SERCA);1型ヒト免疫不全ウイルス(HIV−1)プロテアーゼ;DNAメチルトランスフェラーゼ(DNMT)のうちのいずれか1つ、例えばDNMT1;DNAポリメラーゼ(pol)λ;リボヌクレアーゼ(RNアーゼ)のうちのいずれか1つ、例えばRNアーゼA;リポキシゲナーゼ(LOX)のうちのいずれか1つ;マトリックスメタロプロテイナーゼ(MMP)のうちのいずれか1つ;リゾチーム;プロテインキナーゼC(PKC)ファミリーの酵素のうちのいずれか1つ;細胞性肉腫(c−Src);グリコーゲンシンターゼキナーゼ(GSK)−3β;ErbB2;ホスホリラーゼキナーゼ;タンパク質還元酵素のうちのいずれか1つ、例えばチオレドキシン還元酵素(TrxR)およびアルドース還元酵素(ALR2);チオレドキシン還元酵素;カゼインのうちのいずれか1つ;ヒト血清アルブミン(HSA);ウシ血清アルブミン(BSA);フィブリノーゲン;β−ラクトグロブリン(β−LG);α−ラクトアルブミン;ヒト血清免疫グロブリン(Ig);FtsZ;トランスサイレチン(TTR);グルタチオン(GSH);およびKelch様ECH関連タンパク質1(Keap1)からなる群より選択される、請求項1に記載の組成物。
- 前記ペプチドが、乳清タンパク質、米タンパク質、またはエンドウマメタンパク質である、請求項1に記載の組成物。
- 前記クルクミノイドと前記ペプチドとが、共有結合、イオン性相互作用、親油性(ファンデルワールス)相互作用、または水素結合によって結合される、請求項1に記載の組成物。
- クルクミンと乳清タンパク質との比が、1:1(w/w)(mg:g)、または1:≦10(w/w)(mg:g)、または10:≧1(w/w)(mg:g)、または25:1(w/w)(mg:g)、または1:50(w/w)(mg:g)である、請求項1に記載の組成物。
- 前記クルクミノイド−ペプチド複合体が、前記クルクミノイドと前記ペプチドとを溶媒中で混合する工程によって得られる、請求項1に記載の組成物。
- クルクミノイドを得ることと、
ペプチドを得ることと、
前記クルクミノイドと前記ペプチドとを溶媒中で混合することと
を含む、クルクミノイド−ペプチド複合体を調製する方法。 - 前記クルクミノイドが、クルクミン、デスメトキシクルクミン(DMC)、ビスデスメトキシクルクミン(BDMC)、テトラヒドロクルクミン(THC)、テトラヒドロデスメトキシクルクミン(TDMC)、テトラヒドロビスデスメトキシクルクミンおよび(TBDMC)からなる群より選択される、請求項9に記載の方法。
- 前記ペプチドが、ジペプチド、トリペプチド、オリゴペプチド、ポリペプチド、タンパク質、およびタンパク質フラグメントからなる群より選択される、請求項9に記載の方法。
- 前記ペプチドが、乳清タンパク質、腫瘍壊死因子(TNF−α);シクロオキシゲナーゼ(COX)(COX−1およびCOX−2を含む);α1酸性糖タンパク質(AGP)(オロソムコイドとしても知られる);ミエロイド分化タンパク質2(MD−2);ヒストンアセチル−トランスフェラーゼ(HAT)と呼ばれる酵素のグループのうちのいずれか1つ、p300/CBPなど;ヒストンデアセチラーゼ(HDAC)と呼ばれる酵素のグループのうちのいずれか1つ;グリオキサラーゼI(GLOI);キサンチンオキシダーゼ(XO);プロテアソーム;筋小胞体(小胞体)Ca2+ATPアーゼ(SERCA);1型ヒト免疫不全ウイルス(HIV−1)プロテアーゼ;DNAメチルトランスフェラーゼ(DNMT)のうちのいずれか1つ、例えばDNMT1;DNAポリメラーゼ(pol)λ;リボヌクレアーゼ(RNアーゼ)のうちのいずれか1つ、例えばRNアーゼA;リポキシゲナーゼ(LOX)のうちのいずれか1つ;マトリックスメタロプロテイナーゼ(MMP)のうちのいずれか1つ;リゾチーム;プロテインキナーゼC(PKC)ファミリーの酵素のうちのいずれか1つ;細胞性肉腫(c−Src);グリコーゲンシンターゼキナーゼ(GSK)−3β;ErbB2;ホスホリラーゼキナーゼ;タンパク質還元酵素のうちのいずれか1つ、例えばチオレドキシン還元酵素(TrxR)およびアルドース還元酵素(ALR2);チオレドキシン還元酵素;カゼインのうちのいずれか1つ;ヒト血清アルブミン(HSA);ウシ血清アルブミン(BSA);フィブリノーゲン;β−ラクトグロブリン(β−LG);α−ラクトアルブミン;ヒト血清免疫グロブリン(Ig);FtsZ;トランスサイレチン(TTR);グルタチオン(GSH);およびKelch様ECH関連タンパク質1(Keap1)からなる群より選択される、請求項9に記載の方法。
- 前記溶媒が極性溶媒である、請求項9に記載の方法。
- 前記極性溶媒がアルコールである、請求項13に記載の方法。
- 前記アルコールがエタノールである、請求項14に記載の方法。
- 対象を治療する方法であって、
クルクミン関連障害の治療を必要とする対象を特定することと、
前記対象に請求項1に記載のクルクミノイド−ペプチド複合体を含む治療用組成物を投与することと
を含む、方法。 - 前記クルクミン関連障害が、糖尿病、喘息、アレルギー、白内障、アテローム性動脈硬化症、アルツハイマー病、パーキンソン病、骨髄異形成症候群、嚢胞性線維症、心筋梗塞、高コレステロール症、脳卒中、マラリア、HIV、HSV−1、乾癬、およびその他の障害からなる群より選択される、請求項16に記載の方法。クルクミンが特に改善効果を示す疾患は、多発性硬化症、関節リウマチ、乾癬、炎症性腸疾患、シェーグレン症候群、全身性エリテマトーデス、I型糖尿病、神経変性疾患、および数種類の癌を含む、自己免疫疾患である。
- 投与後のクルクミンの血清中Cmaxが、500ng/mL未満である、請求項16に記載の方法。
- 投与後のクルクミンの血清中Cmaxが、クルクミン投与量の0.001%未満である、請求項16に記載の方法。
- 請求項1に記載のクルクミノイド−ペプチド複合体と薬学的に許容される補形剤、希釈剤、または担体を含む、治療用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461992123P | 2014-05-12 | 2014-05-12 | |
US61/992,123 | 2014-05-12 | ||
PCT/US2015/030434 WO2015175573A1 (en) | 2014-05-12 | 2015-05-12 | Curcumin-peptide conjugates and formulations thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017515911A true JP2017515911A (ja) | 2017-06-15 |
Family
ID=54366874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017512657A Pending JP2017515911A (ja) | 2014-05-12 | 2015-05-12 | クルクミン−ペプチドコンジュゲートおよびその製剤 |
Country Status (13)
Country | Link |
---|---|
US (3) | US10968260B2 (ja) |
EP (1) | EP3142650A4 (ja) |
JP (1) | JP2017515911A (ja) |
KR (1) | KR102567756B1 (ja) |
CN (2) | CN114246849A (ja) |
AU (2) | AU2015259306B2 (ja) |
CA (1) | CA2949069C (ja) |
IL (1) | IL248925A0 (ja) |
MX (1) | MX2016014826A (ja) |
MY (1) | MY186134A (ja) |
RU (1) | RU2744573C2 (ja) |
WO (1) | WO2015175573A1 (ja) |
ZA (1) | ZA201608327B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11185591B2 (en) * | 2016-11-23 | 2021-11-30 | John Robert Chancey | Methods of making and using polyphenols complexed with a protein, peptide, amino acid, polysaccaride, disaccharide, or monosaccharide |
CN107156849A (zh) * | 2017-07-12 | 2017-09-15 | 广州若晖生物科技有限公司 | 一种含姜黄素的关节保健组合物及其应用 |
CN107772479A (zh) * | 2017-11-28 | 2018-03-09 | 吉安市御美丽健康产业股份有限公司 | 一种提高免疫力的乌鸡肽保健食品及其制备方法 |
CN108771664B (zh) * | 2018-06-05 | 2020-09-08 | 中山大学 | 四氢姜黄素在改善过敏性哮喘的应用 |
TW202027734A (zh) * | 2019-04-01 | 2020-08-01 | 許悅郎 | 預防及/或治療失智症之組合物 |
US20230025663A1 (en) | 2021-07-13 | 2023-01-26 | Zeroharm Sciences Private Limited | Nanoformulation with diverse functional molecules from turmeric and process for preparation of the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025623A2 (en) * | 2003-07-28 | 2005-03-24 | Emory University | Ef-24-factor vii conjugates |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011082290A2 (en) | 2009-12-31 | 2011-07-07 | Organomed Corporation | Formulations from natural products, turmeric, and aspirin |
NZ713235A (en) * | 2013-03-15 | 2019-12-20 | Glanbia Nutritionals Ireland Ltd | Product and method for improving bioavailability of therapeutic compounds |
ITMI20132169A1 (it) | 2013-12-20 | 2015-06-21 | Thompson S R L | Composizione per la prevenzione ed il trattamento della bpco e della sintomatologia correlata |
-
2015
- 2015-05-12 MY MYPI2016001999A patent/MY186134A/en unknown
- 2015-05-12 AU AU2015259306A patent/AU2015259306B2/en active Active
- 2015-05-12 US US14/710,578 patent/US10968260B2/en active Active
- 2015-05-12 CN CN202210042718.1A patent/CN114246849A/zh active Pending
- 2015-05-12 CN CN201580030155.2A patent/CN106456577A/zh active Pending
- 2015-05-12 WO PCT/US2015/030434 patent/WO2015175573A1/en active Application Filing
- 2015-05-12 KR KR1020167034380A patent/KR102567756B1/ko active IP Right Grant
- 2015-05-12 RU RU2016147334A patent/RU2744573C2/ru active
- 2015-05-12 CA CA2949069A patent/CA2949069C/en active Active
- 2015-05-12 EP EP15793294.8A patent/EP3142650A4/en active Pending
- 2015-05-12 MX MX2016014826A patent/MX2016014826A/es unknown
- 2015-05-12 JP JP2017512657A patent/JP2017515911A/ja active Pending
-
2016
- 2016-06-20 US US15/187,393 patent/US20160367690A1/en not_active Abandoned
- 2016-11-13 IL IL248925A patent/IL248925A0/en unknown
- 2016-12-05 ZA ZA2016/08327A patent/ZA201608327B/en unknown
-
2020
- 2020-09-01 US US17/008,912 patent/US20200399331A1/en active Pending
- 2020-10-13 AU AU2020256327A patent/AU2020256327A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005025623A2 (en) * | 2003-07-28 | 2005-03-24 | Emory University | Ef-24-factor vii conjugates |
Non-Patent Citations (3)
Title |
---|
J. AGRIC. FOOD CHEM., vol. Vol. 58, No.20, JPN6019002741, 2010, pages p. 11130-11139 * |
J. PHYS. CHEM. B, vol. Vol. 114, No. 9, JPN6019002743, 2010, pages p. 3348-3354 * |
NAT. PROD. REP., vol. Vol. 28, JPN6019002738, 2011, pages p. 1937-1955 * |
Also Published As
Publication number | Publication date |
---|---|
MY186134A (en) | 2021-06-24 |
ZA201608327B (en) | 2022-08-31 |
KR20170003975A (ko) | 2017-01-10 |
CA2949069C (en) | 2022-07-26 |
RU2744573C2 (ru) | 2021-03-11 |
US20160367690A1 (en) | 2016-12-22 |
US10968260B2 (en) | 2021-04-06 |
US20150320878A1 (en) | 2015-11-12 |
WO2015175573A1 (en) | 2015-11-19 |
EP3142650A4 (en) | 2018-01-10 |
CN114246849A (zh) | 2022-03-29 |
AU2020256327A1 (en) | 2020-11-12 |
CN106456577A (zh) | 2017-02-22 |
IL248925A0 (en) | 2017-01-31 |
CA2949069A1 (en) | 2015-11-19 |
US20200399331A1 (en) | 2020-12-24 |
AU2015259306B2 (en) | 2020-08-13 |
AU2015259306A1 (en) | 2016-12-01 |
RU2016147334A3 (ja) | 2018-12-05 |
KR102567756B1 (ko) | 2023-08-17 |
MX2016014826A (es) | 2017-09-28 |
RU2016147334A (ru) | 2018-06-13 |
EP3142650A1 (en) | 2017-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200399331A1 (en) | Curcumin-peptide conjugates and formulations thereof | |
TWI432147B (zh) | 用於促進生長,修復及維持骨及關節之膳食補充品 | |
ES2657364T3 (es) | Formulación de curcumina con una biodisponibilidad mejorada de curcumina y método de preparación y tratamiento de la misma | |
US10729636B2 (en) | Compositions comprising peptide WKDEAGKPLVK | |
Suárez et al. | Effect of amaranth proteins on the RAS system. In vitro, in vivo and ex vivo assays | |
CA3128400A1 (en) | Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, or monosaccharide | |
JPH09502706A (ja) | 胆汁由来免疫調節組成物 | |
US6726932B2 (en) | Fatty acid-containing composition | |
KR101755360B1 (ko) | 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물 | |
JP2012214451A (ja) | 炎症性疾患用アミノ酸組成物 | |
KR20210049698A (ko) | 커큐미노이드계 화합물, 및 감초 추출물 또는 이의 분획물을 포함하는 복합체를 포함하는 돼지 유행성 설사 바이러스 감염의 예방 또는 치료용 조성물 | |
JP2010229118A (ja) | リパーゼ阻害剤 | |
Al Shawoush et al. | Protective effect of Anodonta cygnea hemolymph against acute kidney injury induced by gentamicin in rats | |
TW201919677A (zh) | 藍綠藻萃取物及其製備方法與用途 | |
CN109550041B (zh) | 奥利万星磷酸盐在制备防治牛传染性鼻气管炎药物中的应用 | |
US20160193180A1 (en) | Composition for preventing and treating immune diseases containing daurinol compound as active ingredient | |
US20220047534A1 (en) | Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disaccharide, or monosaccharide | |
RU2613765C1 (ru) | Способ лечения спиноцеребеллярной атаксии | |
Shinde et al. | Human Placenta: potential source of bioactive compounds | |
Hueda et al. | Check Chapter 32 updates | |
JP2014080408A (ja) | ポリアミンを有効成分とする、組織の再生を促進するための組成物 | |
KR20220136909A (ko) | 생활성물질의 경구용 나노입자 및 이의 제조방법 | |
TW201609116A (zh) | 用以治療血管損傷或病變相關疾病之組合物 | |
KR20190059069A (ko) | (2e)-3-(4-하이드록시-3-메톡시페닐)-1-페닐프로프-2-엔-1-온) 화합물의 효능에 따른 관절염의 예방 및 치료를 위한 약학 조성물 | |
JP2005239737A (ja) | 生活の質を改善する新規医薬組成物の製法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180419 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180525 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190426 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190805 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200507 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200507 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200519 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200715 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200721 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20200821 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20200825 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210105 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210323 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210413 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20210525 |
|
C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20210525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211022 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20220329 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20220510 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20220510 |